These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15171614)

  • 21. Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny.
    Schümann M; Dobbelstein M
    Cancer Res; 2006 Feb; 66(3):1282-8. PubMed ID: 16452180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication.
    Young CS
    Curr Top Microbiol Immunol; 1995; 199 ( Pt 2)():89-108. PubMed ID: 7555071
    [No Abstract]   [Full Text] [Related]  

  • 23. The development of conditionally replicative adenoviruses for cancer therapy.
    Curiel DT
    Clin Cancer Res; 2000 Sep; 6(9):3395-9. PubMed ID: 10999720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiencies in Cellular Processes Modulated by the Retinoblastoma Protein Do Not Account for Reduced Human Cytomegalovirus Replication in Its Absence.
    VanDeusen HR; Kalejta RF
    J Virol; 2015 Dec; 89(23):11965-74. PubMed ID: 26378180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of the E2F transcription factor by DNA tumor virus regulatory proteins.
    Cress WD; Nevins JR
    Curr Top Microbiol Immunol; 1996; 208():63-78. PubMed ID: 8575213
    [No Abstract]   [Full Text] [Related]  

  • 26. Infection of cells with replication deficient adenovirus induces cell cycle alterations and leads to downregulation of E2F-1.
    Kuhn H; Liebers U; Gessner C; Karawajew L; Ruppert V; Schumacher A; Witt C; Wolff G
    Biochim Biophys Acta; 2002 Jan; 1542(1-3):106-15. PubMed ID: 11853884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential applications of cell cycle manipulation to clinical response.
    Harris EE; Kao GD; Muschel RJ; McKenna WG
    Cancer Treat Res; 1998; 93():169-90. PubMed ID: 9513781
    [No Abstract]   [Full Text] [Related]  

  • 28. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localization of adenovirus morphogenesis players, together with visualization of assembly intermediates and failed products, favor a model where assembly and packaging occur concurrently at the periphery of the replication center.
    Condezo GN; San Martín C
    PLoS Pathog; 2017 Apr; 13(4):e1006320. PubMed ID: 28448571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
    Moon MS; Lee CJ; Um SJ; Park JS; Yang JM; Hwang ES
    Gynecol Oncol; 2001 Feb; 80(2):168-75. PubMed ID: 11161855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How do animal DNA viruses get to the nucleus?
    Kasamatsu H; Nakanishi A
    Annu Rev Microbiol; 1998; 52():627-86. PubMed ID: 9891810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein.
    Frattini MG; Hurst SD; Lim HB; Swaminathan S; Laimins LA
    EMBO J; 1997 Jan; 16(2):318-31. PubMed ID: 9029152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenoviruses: the nature of the virion and of controlling factors in productive or abortive infection and tumorigenesis.
    Schlesinger RW
    Adv Virus Res; 1969; 14():1-61. PubMed ID: 4304567
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.
    Pipiya T; Sauthoff H; Huang YQ; Chang B; Cheng J; Heitner S; Chen S; Rom WN; Hay JG
    Gene Ther; 2005 Jun; 12(11):911-7. PubMed ID: 15690061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular interactions during adenovirus DNA replication.
    Hay RT; Freeman A; Leith I; Monaghan A; Webster A
    Curr Top Microbiol Immunol; 1995; 199 ( Pt 2)():31-48. PubMed ID: 7555069
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of the adenoviral E4 Orf3 protein on the activity and posttranslational modification of p53.
    DeHart CJ; Perlman DH; Flint SJ
    J Virol; 2015 Mar; 89(6):3209-20. PubMed ID: 25568206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically modified adenoviruses against gliomas: from bench to bedside.
    Gomez-Manzano C; Yung WK; Alemany R; Fueyo J
    Neurology; 2004 Aug; 63(3):418-26. PubMed ID: 15304571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection.
    Brand K; Klocke R; Possling A; Paul D; Strauss M
    Gene Ther; 1999 Jun; 6(6):1054-63. PubMed ID: 10455408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subversion of host defense mechanisms by adenoviruses.
    Burgert HG; Ruzsics Z; Obermeier S; Hilgendorf A; Windheim M; Elsing A
    Curr Top Microbiol Immunol; 2002; 269():273-318. PubMed ID: 12224514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K; Wiewrodt R; Molnar-Kimber K; Jovanovic VP; Amin KM
    Cancer Res; 2002 Jun; 62(12):3438-47. PubMed ID: 12067986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.